These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 32813021)

  • 1. TGF-β1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT.
    Nie E; Jin X; Miao F; Yu T; Zhi T; Shi Z; Wang Y; Zhang J; Xie M; You Y
    Neuro Oncol; 2021 Mar; 23(3):435-446. PubMed ID: 32813021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lnc-TALC promotes O
    Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C
    Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MGMT-inhibitor in combination with TGF-βRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells.
    Das A; Henderson FC; Alshareef M; Porto GBF; Kanginakudru I; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
    Clin Transl Oncol; 2021 Mar; 23(3):612-619. PubMed ID: 32710211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression miR-486-3p Promoted by Allicin Enhances Temozolomide Sensitivity in Glioblastoma Via Targeting MGMT.
    Wu H; Li X; Zhang T; Zhang G; Chen J; Chen L; He M; Hao B; Wang C
    Neuromolecular Med; 2020 Sep; 22(3):359-369. PubMed ID: 32086739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA UCA1/miR-182-5p/MGMT axis modulates glioma cell sensitivity to temozolomide through MGMT-related DNA damage pathways.
    Cheng M; Wang Q; Chen L; Zhao D; Tang J; Xu J; He Z
    Hum Pathol; 2022 May; 123():59-73. PubMed ID: 35219686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT.
    Nie E; Jin X; Wu W; Yu T; Zhou X; Shi Z; Zhang J; Liu N; You Y
    J Neurooncol; 2017 May; 133(1):59-68. PubMed ID: 28425046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma.
    Nie E; Miao F; Jin X; Wu W; Zhou X; Zeng A; Yu T; Zhi T; Shi Z; Wang Y; Zhang J; Liu N; You Y
    Oncogene; 2019 Apr; 38(15):2706-2721. PubMed ID: 30542120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment.
    Das A; Alshareef M; Porto GBF; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
    J Neurol Sci; 2020 Nov; 418():117102. PubMed ID: 32866816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression.
    Kohsaka S; Wang L; Yachi K; Mahabir R; Narita T; Itoh T; Tanino M; Kimura T; Nishihara H; Tanaka S
    Mol Cancer Ther; 2012 Jun; 11(6):1289-99. PubMed ID: 22532597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells.
    Yang B; Ma YB; Chu SH
    Cancer Gene Ther; 2018 Dec; 25(11-12):309-316. PubMed ID: 30140041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-221/222 target the DNA methyltransferase MGMT in glioma cells.
    Quintavalle C; Mangani D; Roscigno G; Romano G; Diaz-Lagares A; Iaboni M; Donnarumma E; Fiore D; De Marinis P; Soini Y; Esteller M; Condorelli G
    PLoS One; 2013; 8(9):e74466. PubMed ID: 24147153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastasis-enhancing protein KITENIN confers temozolomide resistance on glioblastoma with unmethylated MGMT via upregulation of cancer stem cell makers.
    Ahn EJ; Kim YJ; Akanda MR; Oh SJ; Jung TY; Jung S; Lee JH; Kim SS; Jeong YY; Ha HH; Hyun H; Kim H; Rhee JH; Kim KK; Lee KH; Moon KS
    Clin Transl Med; 2024 Aug; 14(8):e1804. PubMed ID: 39118288
    [No Abstract]   [Full Text] [Related]  

  • 14. A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastoma.
    Zhao J; Yang S; Cui X; Wang Q; Yang E; Tong F; Hong B; Xiao M; Xin L; Xu C; Tan Y; Kang C
    Neuro Oncol; 2023 May; 25(5):857-870. PubMed ID: 36272139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EPIC-0307-mediated selective disruption of PRADX-EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT.
    Xin L; Tan Y; Zhu Y; Cui X; Wang Q; Zhao J; Tian S; Xu C; Xiao M; Hong B; Xu J; Yuan X; Wang C; Kang C; Fang C
    Neuro Oncol; 2023 Nov; 25(11):1976-1988. PubMed ID: 37279651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression.
    Okada M; Sato A; Shibuya K; Watanabe E; Seino S; Suzuki S; Seino M; Narita Y; Shibui S; Kayama T; Kitanaka C
    Int J Oncol; 2014 Feb; 44(2):591-9. PubMed ID: 24316756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
    Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X
    Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
    Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
    Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.
    Nguyen SA; Stechishin OD; Luchman HA; Lun XQ; Senger DL; Robbins SM; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Sep; 20(18):4894-903. PubMed ID: 25078279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HOXD-AS2-STAT3 feedback loop attenuates sensitivity to temozolomide in glioblastoma.
    Zhang ZX; Ren P; Cao YY; Wang TT; Huang GH; Li Y; Zhou S; Yang W; Yang L; Liu GL; Xiang Y; Pei YC; Chen QZ; Chen JX; Lv SQ
    CNS Neurosci Ther; 2023 Nov; 29(11):3430-3445. PubMed ID: 37308741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.